Trending News

Changes to Civil Rights Enforcement: New Executive Order Eliminates Disparate-Impact Liability in Federal Regulations

How Are Family Offices Building Smarter Wealth? Structural Alpha (11 Examples)

DOJ Rule Restricting Sensitive Data Transfers Takes Effect

The Trump Administration’s Diversity, Equity, and Inclusion (DEI) Executive Orders: A Brief Primer

Trump Administration Announces "Reciprocal" Tariffs

What Every Multinational Company Should Know About … The Global and Reciprocal Tariffs Announcement

Blockading the Ports: U.S. Imposes 10% Global Tariff; Higher Reciprocal Tariff Rates by Country

Fifth Circuit Court of Appeals Negates Ruling on Federal Contractor Minimum Wage

New Executive Order Rescinds the $17.75 Per Hour Federal Contractor Minimum Wage

Medicare Telehealth Gets Another Temporary Lifeline – Will Congress Make it Permanent?

GlobeNewswire Biotech

Website

www.globenewswire.com

Featured Biotech Press Releases From GlobeNewswire

NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation
Posted On Friday, February 14, 2025
Fate Therapeutics to Present at Upcoming Investor Conferences
Posted On Friday, February 14, 2025
Entero Therapeutics Appoints Richard Paolone as CEO
Posted On Friday, February 14, 2025
Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity
Posted On Friday, February 14, 2025
Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025
Posted On Friday, February 14, 2025
IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML
Posted On Friday, February 14, 2025
Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex®
Posted On Friday, February 14, 2025
Ensho Therapeutics Announces Upcoming Presentation at ECCO 2025 of Phase 1, Once-Daily Dosing Data for NSHO-101, an Oral α4β7 Inhibitor for Inflammatory Bowel Disease
Posted On Friday, February 14, 2025
Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update
Posted On Friday, February 14, 2025
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update
Posted On Friday, February 14, 2025
Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific Conference
Posted On Friday, February 14, 2025
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
Posted On Friday, February 14, 2025
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025
Posted On Friday, February 14, 2025
Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
Posted On Friday, February 14, 2025
Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™
Posted On Friday, February 14, 2025
Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
Posted On Friday, February 14, 2025
Volta Medical Artificial Intelligence-guided Cardiac Ablation Procedure Improves Treatment of Atrial Fibrillation
Posted On Friday, February 14, 2025
Nxera Pharma Proposes Changes to its Board of Directors
Posted On Friday, February 14, 2025
Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2024
Posted On Friday, February 14, 2025
Theratechnologies Resumes Distribution of EGRIFTA SV®
Posted On Thursday, February 13, 2025
Peptone Market to Reach $240.5 million, Globally, by 2035 at 4.2% CAGR: Allied Market Research
Posted On Thursday, February 13, 2025
Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors
Posted On Thursday, February 13, 2025
Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans
Posted On Thursday, February 13, 2025
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
Posted On Thursday, February 13, 2025
Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology
Posted On Thursday, February 13, 2025

Print